Stockscreener 앱 받기
4.60
5.35%
-0.26
시간 외 거래:
4.50
-0.10
-2.17%
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M - MarketBeat
Jones Trading reiterates Perspective Therapeutics stock Buy rating By Investing.com - Investing.com India
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Jones Trading reiterates Perspective Therapeutics stock Buy rating - Investing.com
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | CATX Stock News - GuruFocus
B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price - MarketBeat
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | - GuruFocus
Perspective Therapeutics (CATX) Receives Boost from UBS with Rai - GuruFocus
Perspective Therapeutics price target raised to $13 from $11 at B. Riley - TipRanks
UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating - marketscreener.com
UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock - MarketBeat
Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating - marketscreener.com
Perspective Therapeutics (CATX) to Release Earnings on Wednesday - MarketBeat
RBC cuts Perspective Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Perspective Therapeutics Q4 2025 earnings preview - MSN
Perspective Therapeutics to share tumor therapy data at 2026 cancer meeting - Stock Titan
Truist reiterates Buy on Perspective Therapeutics stock By Investing.com - Investing.com Canada
BTIG Reiterates Buy Rating for CATX with $14 Price Target | CATX Stock News - GuruFocus
Royal Bank Of Canada Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00 - MarketBeat
RBC Capital Lowers Price Target for CATX While Maintaining 'Outp - GuruFocus
Truist reiterates Buy on Perspective Therapeutics stock - Investing.com
RBC cuts Perspective Therapeutics stock price target on model updates - Investing.com
Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform By Investing.com - Investing.com South Africa
Perspective Therapeutics stock rating reiterated at Buy by BTIG - Investing.com India
Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives "Buy" Rating from BTIG Research - MarketBeat
Perspective Therapeutics, Inc. 2025 10-K Report: Advancing Targeted Alpha Therapy Radiopharmaceuticals for Cancer Treatment - Minichart
Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 4.4%Here's What Happened - MarketBeat
Perspective Therapeutics earnings missed by $0.16, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics Reports 2025 Results, Highlights Pipeline Progress - TipRanks
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Perspective Therapeutics (NYSE: CATX) expands targeted alpha cancer pipeline - Stock Titan
CATX: Clinical pipeline advances with strong safety, efficacy, and funding to support growth into 2027 - TradingView
Perspective Therapeutics (NYSE: CATX) details 2025 loss and cash runway to 2027 - Stock Titan
BRIEF-Perspective Therapeutics FY EPS USD -1.4 - TradingView
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results - GlobeNewswire
Perspective Therapeutics (CATX) Set to Release Q4 Earnings - GuruFocus
Can Perspective Therapeutics Inc expand into new markets2026 Price Targets & Community Consensus Trade Alerts - baoquankhu1.vn
Trading Recap: What is the next catalyst for Perspective Therapeutics IncBull Run & Trade Opportunity Analysis - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Perspective Therapeutics, Inc. Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Avidity group holds 6.05M shares in CATX (NASDAQ: CATX) - Stock Titan
Jobs Data: Is Perspective Therapeutics Inc stock a hidden gemGap Down & Long-Term Safe Investment Ideas - baoquankhu1.vn
Aug Sentiment: Is Perspective Therapeutics Inc part of any ETF2026 Price Targets & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), ArriVent BioPharma, Inc. (AVBP) and Evommune, Inc. (EVMN) - The Globe and Mail
CATX SEC FilingsPerspective Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Perspective Therapeutics (CATX) director awarded 50,000-share stock option grant - Stock Titan
Director at Perspective Therapeutics (CATX) awarded 50,000 stock options - Stock Titan
Director at Perspective Therapeutics (CATX) awarded 50K stock options - Stock Titan
Director at Perspective Therapeutics (CATX) awarded 50,000-share stock option grant - Stock Titan
Director at Perspective Therapeutics (CATX) awarded 50,000 stock options for 2026 - Stock Titan
Perspective Therapeutics (CATX) CEO receives 735,000-option 2026 equity grant - Stock Titan
Perspective Therapeutics (CATX) CAO receives 90,000-stock-option equity award - Stock Titan
Perspective Therapeutics (CATX) CMO receives 150,000 stock options as 2026 award - Stock Titan
CATX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
0.85%
1.86%
자본화:
|
볼륨(24시간):